Fabio L Cury

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/7799949/publications.pdf

Version: 2024-02-01

64 papers	930 citations	430874 18 h-index	501196 28 g-index
65 all docs	65 docs citations	65 times ranked	1434 citing authors

#	Article	IF	Citations
1	NRG Oncology Updated International Consensus Atlas on Pelvic Lymph Node Volumes for Intact and Postoperative Prostate Cancer. International Journal of Radiation Oncology Biology Physics, 2021, 109, 174-185.	0.8	77
2	Hypofractionated Intensity Modulated Radiation Therapy in Combined Modality Treatment for Bladder Preservation in Elderly Patients With Invasive Bladder Cancer. International Journal of Radiation Oncology Biology Physics, 2014, 88, 326-331.	0.8	72
3	The Role of HMGB1 in Radioresistance of Bladder Cancer. Molecular Cancer Therapeutics, 2016, 15, 471-479.	4.1	58
4	Brachytherapy Improves Biochemical Failureâ€“Free Survival in Low- and Intermediate-Risk Prostate Cancer Compared With Conventionally Fractionated External Beam Radiation Therapy: A Propensity Score Matched Analysis. International Journal of Radiation Oncology Biology Physics, 2015, 91, 505-516.	0.8	57
5	Hypofractionated Radiotherapy for Favorable Risk Prostate Cancer. International Journal of Radiation Oncology Biology Physics, 2010, 77, 805-810.	0.8	38
6	The prostate cancer risk stratification (ProCaRS) project: Recursive partitioning risk stratification analysis. Radiotherapy and Oncology, 2013, 109, 204-210.	0.6	34
7	Combined radiotherapy and immunotherapy in urothelial bladder cancer: harnessing the full potential of the anti-tumor immune response. World Journal of Urology, 2021, 39, 1331-1343.	2.2	34
8	Drug costs in the management of metastatic castration-resistant prostate cancer in Canada. BMC Health Services Research, 2014, 14, 252.	2.2	31
9	Evaluation of New Tests and Interventions for Prostate Cancer Management: A Systematic Review. Journal of the National Comprehensive Cancer Network: JNCCN, 2018, 16, 1340-1351.	4.9	30
10	Hypofractionated Radiation Therapy (66 Gy in 22 Fractions at 3 Gy per Fraction) for Favorable-Risk Prostate Cancer: Long-term Outcomes. International Journal of Radiation Oncology Biology Physics, 2013, 86, 534-539.	0.8	27
11	Phase 1 Trial of Atezolizumab Plus Trimodal Therapy in Patients With Localized Muscle-Invasive Bladder Cancer. International Journal of Radiation Oncology Biology Physics, 2021, 110, 738-741.	0.8	27
12	Combining mTOR Inhibition with Radiation Improves Antitumor Activity in Bladder Cancer Cells In Vitro and In Vivo: A Novel Strategy for Treatment. PLoS ONE, 2013, 8, e65257.	2.5	26
13	Contrasting analytical and data-driven frameworks for radiogenomic modeling of normal tissue toxicities in prostate cancer. Radiotherapy and Oncology, 2015, 115, 107-113.	0.6	24
14	Management of localized and advanced prostate cancer in Canada: A lifetime cost and qualityâ€adjusted lifeâ€year analysis. Cancer, 2016, 122, 1085-1096.	4.1	21
15	Abscopal Effect in a Stage IV Melanoma Patient who Progressed on Pembrolizumab. Cureus, 2018, 10, e2238.	0.5	20
16	Practical considerations for prostate hypofractionation in the developing world. Nature Reviews Urology, 2021, 18, 669-685.	3.8	20
17	Active surveillance for low-risk prostate cancer compared with immediate treatment: a Canadian cost comparison. CMAJ Open, 2014, 2, E60-E68.	2.4	19
18	Single-Fraction High-Dose-Rate Brachytherapy and Hypofractionated External Beam Radiation Therapy in the Treatment of Intermediate-Risk Prostate Cancer â€“ Long Term Results. International Journal of Radiation Oncology Biology Physics, 2012, 82, 1417-1423.	0.8	18

#	Article	IF	Citations
19	Prostateâ€specific antigen response after shortâ€term hormone therapy plus externalâ€beam radiotherapy and outcome in patients treated on Radiation Therapy Oncology Group study 9413. Cancer, 2013, 119, 1999-2004.	4.1	18
20	Electrochemical red-ox therapy of prostate cancer in nude mice. Bioelectrochemistry, 2015, 104, 1-9.	4.6	18
21	Improving ultrasound-based prostate volume estimation. BMC Urology, 2019, 19, 68.	1.4	18
22	Dosimetric consequences of misalignment and realignment in prostate 3DCRT using intramodality ultrasound image guidance. Medical Physics, 2010, 37, 2787-2795.	3.0	17
23	Refining the orthotopic dog prostate cancer (DPC)â€1 model to better bridge the gap between rodents and men. Prostate, 2012, 72, 752-761.	2.3	17
24	Novel knowledge-based treatment planning model for hypofractionated radiotherapy of prostate cancer patients. Physica Medica, 2020, 69, 36-43.	0.7	16
25	Radiation therapy and androgen deprivation in the management of high risk prostate cancer. International Braz J Urol: Official Journal of the Brazilian Society of Urology, 2011, 37, 161-179.	1.5	15
26	Treating intermediate-risk prostate cancer with hypofractionated external beam radiotherapy alone. Radiotherapy and Oncology, 2011, 101, 486-489.	0.6	14
27	Prostate gland edema after single-fraction high-dose rate brachytherapy before external beam radiation therapy. Brachytherapy, 2010, 9, 208-212.	0.5	13
28	The Prostate Cancer Risk Stratification Project: Database Construction and Risk Stratification Outcome Analysis. Journal of the National Comprehensive Cancer Network: JNCCN, 2014, 12, 60-69.	4.9	12
29	Impact of abiraterone acetate with and without prior docetaxel chemotherapy on the survival of patients with metastatic castration-resistant prostate cancer: a population-based study. CMAJ Open, 2017, 5, E265-E272.	2.4	12
30	Endoscopic Vascular Targeted Photodynamic Therapy with the Photosensitizer WST11 for Benign Prostatic Hyperplasia in the Preclinical Dog Model. Journal of Urology, 2013, 190, 1946-1953.	0.4	11
31	Acute and late toxicity in high-risk prostate cancer patients treated with androgen suppression and hypofractionated pelvic radiation therapy. Practical Radiation Oncology, 2017, 7, 264-269.	2.1	11
32	Clinical Management and Burden of Prostate Cancer: A Markov Monte Carlo Model. PLoS ONE, 2014, 9, e113432.	2.5	10
33	Contemporary outcome and management of patients who had an aborted cystectomy due to unresectable bladder cancer. Urologic Oncology: Seminars and Original Investigations, 2011, 29, 309-313.	1.6	9
34	Prostate-specific antigen bounce after high-dose-rate prostate brachytherapy and hypofractionated external beam radiotherapy. Brachytherapy, 2014, 13, 450-455.	0.5	9
35	Phase I Clinical Trial of Everolimus Combined with Trimodality Therapy in Patients with Muscle-Invasive Bladder Cancer. Bladder Cancer, 2017, 3, 105-112.	0.4	9
36	Long-Term Results of Moderate Hypofractionation to Prostate and Pelvic Nodes Plus Androgen Suppression in High-Risk Prostate Cancer. Practical Radiation Oncology, 2020, 10, e514-e520.	2.1	9

#	Article	IF	Citations
37	Organ-sparing strategies in the management of invasive bladder cancer. Expert Review of Anticancer Therapy, 2009, 9, 1765-1775.	2.4	8
38	Anisotropic Bladder Planning Target Volume in Bladder Radiation Therapy. Practical Radiation Oncology, 2019, 9, 24-28.	2.1	7
39	Role of Serum Lymphocyte-derived Biomarkers in Nonmetastatic Muscle-invasive Bladder Cancer Patients Treated with Trimodal Therapy. European Urology Open Science, 2022, 36, 26-33.	0.4	6
40	Pelvic lymph node displacement in high-risk prostate cancer patients treated with image guided intensity modulated radiation therapy with 2 independent target volumes. Practical Radiation Oncology, 2015, 5, 406-410.	2.1	5
41	Refining assessment of response to radiation-based therapy for muscle-invasive bladder cancer: Is post-treatment tumor bed biopsy always necessary?. Urologic Oncology: Seminars and Original Investigations, 2021, 39, 299.e7-299.e14.	1.6	5
42	Meta-analysis of Elective Pelvic Nodal Irradiation Using Moderate Hypofractionation for High-Risk Prostate Cancer. International Journal of Radiation Oncology Biology Physics, 2022, 113, 1044-1053.	0.8	5
43	Evaluation of a prototype 3D ultrasound system for multimodality imaging of cervical nodes for adaptive radiation therapy. , 2007, , .		3
44	Impact of the introduction of novel hormonal agents on metastatic castration-resistant prostate cancer treatment choice. Journal of Oncology Pharmacy Practice, 2020, 26, 293-305.	0.9	3
45	Stereotactic Ablative Radiation Therapy for the Treatment of Upper Urinary Tract Urothelial Carcinoma. Practical Radiation Oncology, 2022, 12, e34-e39.	2.1	3
46	MP61-08â€ƒA PHASE I/II TRIAL OF TRANSURETHRAL SURGERY FOLLOWED BY A COMBINATION OF ATEZOLIZUMAB AN ANTI-PDL-1 (MPDL3280A) WITH TRIMODAL THERAPY IN PATIENTS WITH MUSCLE-INVASIVE BLADDER CANCER. Journal of Urology, 2020, 203, e938.	0.4	3
47	Impact of sarcopenia on outcomes of patients treated with trimodal therapy for muscle invasive bladder cancer. Urologic Oncology: Seminars and Original Investigations, 2022, 40, 194.e15-194.e22.	1.6	3
48	Moderate hypofractionated external beam radiotherapy alone for intermediate risk prostate cancer: long term outcomes. Canadian Journal of Urology, 2016, 23, 8209-14.	0.0	3
49	Trimodal therapy vs. radical cystectomy for muscle-invasive bladder cancer: A Canadian cost-effectiveness analysis. Canadian Urological Association Journal, 2022, 16, .	0.6	2
50	Comparison of Surgery and Radiation as Local Treatments in the Risk of Locoregional Complications in Men Subsequently Dying From Prostate Cancer. Clinical Genitourinary Cancer, 2018, 16, e201-e210.	1.9	1
51	Psychological functioning, coping styles and their relationship to appraisal of physical limitations following invasive surgical procedures for softâ€tissue sarcoma: A qualitative study. Journal of Surgical Oncology, 2020, 121, 1266-1275.	1.7	1
52	222 ACTIVE SURVEILLANCE FOR EARLY PROSTATE CANCER COMPARED WITH IMMEDIATE TREATMENT: A UNITED STATES - CANADIAN ECONOMIC COMPARISON. Journal of Urology, 2013, 189, .	0.4	0
53	MP46-18 USE OF ABIRATERONE ACETATE IN THE MANAGEMENT OF CASTRATION-RESISTANT PROSTATE CANCER: A REAL-LIFE COST EFFECTIVENESS STUDY. Journal of Urology, 2016, 195, .	0.4	0
54	MP46-19 CASTRATION-RESISTANT PROSTATE CANCER PATIENTS IN QUEBEC: MEDICATION USE IN THE LAST YEAR OF LIFE. Journal of Urology, 2016, 195, .	0.4	0

#	Article	IF	Citations
55	PD24-05 IMPACT OF ABIRATERONE ACETATE IN THE POST-DOCETAXEL SETTING ON THE SURVIVAL OF METASTATIC CASTRATION-RESISTANT PROSTATE CANCER PATIENTS: A POPULATION-BASED STUDY IN QUEBEC. Journal of Urology, 2017, 197, .	0.4	0
56	External validation of the ProCaRS nomograms and comparison of existing risk-stratification tools for localized prostate cancer. Canadian Urological Association Journal, 2017, 11, 94.	0.6	0
57	Supplementary data: External validation of the ProCaRS nomograms and comparison of existing risk-stratification tools for localized prostate cancer. Canadian Urological Association Journal, 2017, 11, 126.	0.6	0
58	Abstract 1452: mTOR inhibition radiosensitizes bladder cancer tumor cellsin vitroandin vivo: A novel strategy for treatment. , 2012, , .		0
59	Hypofractionated radiotherapy (66Gy at 3Gy per fraction) for favorable-risk prostate cancer: Long-term outcomes.. Journal of Clinical Oncology, 2013, 31, 141-141.	1.6	0
60	Canadian cost comparison of different forms of androgen ablative therapies prior and during the castration-resistant prostate cancer.. Journal of Clinical Oncology, 2014, 32, e16029-e16029.	1.6	0
61	Current era clinical outcomes of castration-resistant prostate cancer in real-life population study in Quebec, Canada.. Journal of Clinical Oncology, 2015, 33, 226-226.	1.6	0
62	Abstract 3316: The role of high mobility group box 1 in the combination therapy of gemcitabine and radiation in muscle invasive bladder cancer. , 2015, , .		0
63	Abstract 1654: p21 WAF1/Cip1 -mediated radiosensitization of bladder cancer cells by mTOR inhibitor, RAD001 disrupts the balance between autophagy and apoptosis. , 2016, , .		0
64	Acute and late toxicity in high-risk prostate cancer patients treated with androgen suppression and hypofractionated pelvic radiotherapy.. Journal of Clinical Oncology, 2017, 35, 47-47.	1.6	0